Men's Share of Prescription Fills for GIP and GLP-1 Agonists

(Please use a modern browser to see the interactive version of this visualization)

Data reflect retail prescription fills from January 1, 2022, through June 15, 2026. Medications were grouped by FDA-approved, on-label indication. Weight-loss medications include Zepbound, Wegovy, Foundayo, Saxenda, and liraglutide (Saxenda). Type 2 diabetes medications include Ozempic, Mounjaro, Victoza, and liraglutide (Victoza).